{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T10:07:43Z","timestamp":1775556463296,"version":"3.50.1"},"reference-count":83,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jaip.2026.01.044","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T09:35:06Z","timestamp":1775554506000},"page":"762-770","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biologics and Novel Therapeutics in Food Allergy"],"prefix":"10.1016","volume":"14","author":[{"given":"Brent","family":"Anderson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Pascal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Gohazrua K.","family":"Butler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew R.","family":"Chin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayantani B.","family":"Sindher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aikaterini","family":"Anagnostou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Arasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"B\u00e9gin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina E.","family":"Ciaccio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Eiwegger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Fiocchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Fleischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Garcia-Llorett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edwin H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahida Rani","family":"Maskatia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten P.","family":"Perrett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wayne","family":"Shreffler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Upton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2467-4256","authenticated-orcid":false,"given":"R. Sharon","family":"Chinthrajah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2026.01.044_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2024.10.020","article-title":"Anti-IgE and food allergy","volume":"155","author":"Dantzer","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.044_bib2","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jaip.2023.11.032","article-title":"The role of biologics in the treatment of food allergy","volume":"12","author":"Sindher","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.044_bib3","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.jaip.2019.01.023","article-title":"Impact of omalizumab on food allergy in patients treated for asthma: a real-life study","volume":"7","author":"Fiocchi","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.044_bib4","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/eji.201847668","article-title":"Omalizumab dampens type 2 inflammation in a group of long-term treated asthma patients and detaches IgE from FcepsilonRI","volume":"48","author":"Maggi","year":"2018","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jaip.2026.01.044_bib5","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jaci.2004.06.032","article-title":"Omalizumab-induced reductions in mast cell Fce psilon RI expression and function","volume":"114","author":"Beck","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.044_bib6","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJMoa2312382","article-title":"Omalizumab for the treatment of multiple food allergies","volume":"390","author":"Wood","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2026.01.044_bib7","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/all.16314","article-title":"Omalizumab reduces anaphylactic reactions and allows food introduction in food-allergic in children with severe asthma: an observational study","volume":"80","author":"Arasi","year":"2025","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2026.01.044_bib8","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jaci.2025.10.031","article-title":"Exploratory analyses of predictors and correlates of response to omalizumab therapy in patients with multiple food allergies","volume":"157","author":"Chinthrajah","year":"2026","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.044_bib9","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jaci.2007.11.026","article-title":"Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy","volume":"121","author":"Corren","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.044_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2025.101113","article-title":"A World Allergy Organization (WAO) manifesto for the worldwide approval of biologic therapies for food allergy","volume":"18","author":"Fiocchi","year":"2025","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaip.2026.01.044_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-16730-6","article-title":"Oral immunotherapy combined with omalizumab for high-risk cow's milk allergy: a randomized controlled trial","volume":"7","author":"Takahashi","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaip.2026.01.044_bib12","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.jaci.2015.10.005","article-title":"A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy","volume":"137","author":"Wood","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.044_bib13","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.jaci.2011.04.009","article-title":"Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy","volume":"127","author":"Nadeau","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.044_bib14","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jaci.2013.09.046","article-title":"A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients","volume":"132","author":"Schneider","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.044_bib15","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jaci.2016.08.010","article-title":"Omalizumab facilitates rapid oral desensitization for peanut allergy","volume":"139","author":"MacGinnitie","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.044_bib16","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1111\/cea.13469","article-title":"Individually dosed omalizumab facilitates peanut oral immunotherapy in peanut allergic adolescents","volume":"49","author":"Brandstrom","year":"2019","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2026.01.044_bib17","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1111\/pai.13517","article-title":"Oral immunotherapy in severe cow's milk allergic patients treated with omalizumab: real life survey from a Spanish registry","volume":"32","author":"Ibanez-Sandin","year":"2021","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaip.2026.01.044_bib18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1710-1492-10-7","article-title":"Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using omalizumab","volume":"10","author":"Begin","year":"2014","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.044_bib19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.eclinm.2018.12.006","article-title":"A phase 2 randomized controlled multisite study using omalizumab-facilitated rapid desensitization to test continued vs discontinued dosing in multifood allergic individuals","volume":"7","author":"Andorf","year":"2019","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jaip.2026.01.044_bib20","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S2468-1253(17)30392-8","article-title":"Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial","volume":"3","author":"Andorf","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jaip.2026.01.044_bib21","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1111\/all.15217","article-title":"Phase 2, randomized multi oral immunotherapy with omalizumab 'real life' study","volume":"77","author":"Sindher","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2026.01.044_bib22","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/alr.23268","article-title":"Combination of omalizumab with allergen immunotherapy versus immunotherapy alone for allergic diseases: a meta-analysis of randomized controlled trials","volume":"14","author":"Zhang","year":"2024","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaip.2026.01.044_bib23","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3390\/ph18030437","article-title":"Omalizumab and oral immunotherapy in IgE-mediated food allergy in children: a systematic review and a meta-analysis","volume":"18","author":"Buono","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jaip.2026.01.044_bib24","article-title":"The role of omalizumab as an adjunct to oral immunotherapy in pediatric food allergy: a systematic review","volume":"17","author":"Khidir Mustafa","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.jaip.2026.01.044_bib25","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jaci.2020.08.039","article-title":"Determinants of omalizumab dose-related efficacy in oral immunotherapy: evidence from a cohort of 181 patients","volume":"147","author":"Azzano","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.044_bib26","doi-asserted-by":"crossref","first-page":"AB444","DOI":"10.1016\/j.jaci.2024.12.1022","article-title":"Treatment of multi-food allergy with omalizumab compared to omalizumab-facilitated multi-allergen OIT","volume":"155","author":"Wood","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.044_bib27","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/ACI.0000000000000744","article-title":"Omalizumab as monotherapy for food allergy","volume":"21","author":"Arasi","year":"2021","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.044_bib28","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.pupt.2014.03.003","article-title":"Omalizumab in patients with allergic (IgE-mediated) asthma and IgE\/bodyweight combinations above those in the initially approved dosing table","volume":"28","author":"Kornmann","year":"2014","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.jaip.2026.01.044_bib29","doi-asserted-by":"crossref","DOI":"10.1111\/pai.14057","article-title":"Omalizumab in severe asthma and food allergies with IgE levels >1500 kU\/L: two-year evaluation","volume":"34","author":"Dinardo","year":"2023","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaip.2026.01.044_bib30","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13223-020-00419-z","article-title":"Protocol for a double-blind, randomized controlled trial on the dose-related efficacy of omalizumab in multi-food oral immunotherapy","volume":"16","author":"Langlois","year":"2020","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.044_bib31","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1016\/j.jaip.2024.08.056","article-title":"Omalizumab implementation in practice: lessons learned from the OUtMATCH study","volume":"12","author":"Vickery","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.044_bib32","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/j.1365-2125.2011.03962.x","article-title":"Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE","volume":"72","author":"Lowe","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jaip.2026.01.044_bib33","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jaci.2025.05.014","article-title":"Introduction of allergenic foods after treatment with omalizumab","volume":"156","author":"Dantzer","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.044_bib34","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/ACI.0000000000001058","article-title":"New approaches in childhood IgE-mediated food allergy treatment","volume":"25","author":"Gurel","year":"2025","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.044_bib35","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jaip.2025.10.007","article-title":"Peanut oral immunotherapy using 30 mg and 300 mg maintenance doses","volume":"14","author":"Upton","year":"2026","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.044_bib36","article-title":"ADP101 multifood oral immunotherapy for food-allergic patients: Harmony phase 1\/2 randomized clinical trial","volume":"4","author":"Kim","year":"2025","journal-title":"J Allergy Clin Immunol Glob"},{"key":"10.1016\/j.jaip.2026.01.044_bib37","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.jaci.2023.01.036","article-title":"Open-label study of the efficacy, safety, and durability of peanut sublingual immunotherapy in peanut-allergic children","volume":"151","author":"Kim","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.044_bib38","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaci.2023.08.032","article-title":"Desensitization and remission after peanut sublingual immunotherapy in 1- to 4-year-old peanut-allergic children: a randomized, placebo-controlled trial","volume":"153","author":"Kim","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.044_bib39","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jaci.2005.08.027","article-title":"Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract","volume":"116","author":"Enrique","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.044_bib40","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.jaci.2019.07.030","article-title":"Long-term sublingual immunotherapy for peanut allergy in children: clinical and immunologic evidence of desensitization","volume":"144","author":"Kim","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.044_bib41","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.jaci.2014.12.1917","article-title":"Sublingual immunotherapy for peanut allergy: long-term follow-up of a randomized multicenter trial","volume":"135","author":"Burks","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.044_bib42","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.jaci.2010.12.1083","article-title":"Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization","volume":"127","author":"Kim","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.044_bib43","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jaci.2012.11.011","article-title":"Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial","volume":"131","author":"Fleischer","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.044_bib44","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.jaci.2014.11.005","article-title":"A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy","volume":"135","author":"Narisety","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.044_bib45","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.anai.2025.01.013","article-title":"Randomized, placebo-controlled, phase 1 safety study of oral mucosal immunotherapy in adults with peanut allergy","volume":"134","author":"Berger","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2026.01.044_bib46","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1056\/NEJMoa2212895","article-title":"Phase 3 trial of epicutaneous immunotherapy in toddlers with peanut allergy","volume":"388","author":"Greenhawt","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2026.01.044_bib47","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jaci.2020.11.027","article-title":"Epicutaneous immunotherapy for treatment of peanut allergy: follow-up from the Consortium for Food Allergy Research","volume":"147","author":"Scurlock","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.044_bib48","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.jaci.2016.08.017","article-title":"Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults","volume":"139","author":"Jones","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.044_bib49","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.anai.2019.08.007","article-title":"Estimated risk reduction to packaged food reactions by epicutaneous immunotherapy (EPIT) for peanut allergy","volume":"123","author":"Remington","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2026.01.044_bib50","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.jaip.2025.02.024","article-title":"Long-term safety of epicutaneous immunotherapy in peanut-allergic children: an open-label active treatment (REALISE study)","volume":"13","author":"Pongracic","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.044_bib51","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.jaip.2025.02.004","article-title":"Efficacy and safety of epicutaneous immunotherapy in peanut-allergic toddlers: open-label extension to EPITOPE","volume":"13","author":"Greenhawt","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.044_bib52","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.anai.2025.04.002","article-title":"Efficacy and safety of epicutaneous immunotherapy in children with peanut allergy with atopic comorbidities","volume":"135","author":"Scurlock","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2026.01.044_bib53","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1016\/j.jaip.2021.11.017","article-title":"Safety of epicutaneous immunotherapy in peanut-allergic children: REALISE randomized clinical trial results","volume":"10","author":"Pongracic","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.044_bib54","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaci.2020.06.028","article-title":"Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year results","volume":"146","author":"Fleischer","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.044_bib55","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1001\/jamapediatrics.2023.6630","article-title":"Varying doses of epicutaneous immunotherapy with Viaskin milk vs placebo in children with cow's milk allergy: a randomized clinical trial","volume":"178","author":"Petroni","year":"2024","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.jaip.2026.01.044_bib56","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.jaci.2016.01.008","article-title":"Safety of epicutaneous immunotherapy for the treatment of peanut allergy: a phase 1 study using the Viaskin patch","volume":"137","author":"Jones","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.044_bib57","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1001\/jama.2019.1113","article-title":"Effect of epicutaneous immunotherapy vs placebo on reaction to peanut protein ingestion among children with peanut allergy: the PEPITES randomized clinical trial","volume":"321","author":"Fleischer","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jaip.2026.01.044_bib58","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1001\/jama.2017.16591","article-title":"Effect of varying doses of epicutaneous immunotherapy vs placebo on reaction to peanut protein exposure among patients with peanut sensitivity: a randomized clinical trial","volume":"318","author":"Sampson","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jaip.2026.01.044_bib59","doi-asserted-by":"crossref","first-page":"AB194","DOI":"10.1016\/j.jaci.2021.12.637","article-title":"Development of a multifunctional third generation anti-IgE therapeutic candidate antibody","volume":"149","author":"Becklund","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.044_bib60","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.jaci.2025.05.028","article-title":"High-affinity omalizumab variants with optimized disruptive potency prevent anaphylaxis in vivo","volume":"156","author":"Brigger","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.044_bib61","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70264","article-title":"Safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity profiles of a single-dose JYB1904 in healthy Chinese participants: a phase Ia, randomized, double-blind, placebo-controlled study","volume":"18","author":"Shen","year":"2025","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jaip.2026.01.044_bib62","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.131347","article-title":"Phase 2a randomized, placebo-controlled study of anti-IL-33 in peanut allergy","volume":"4","author":"Chinthrajah","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.jaip.2026.01.044_bib63","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/all.16404","article-title":"Efficacy and safety of dupilumab in children with peanut allergy: a multicenter, open-label, phase II study","volume":"80","author":"Sindher","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2026.01.044_bib64","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/all.16420","article-title":"Dupilumab as an adjunct to oral immunotherapy in pediatric patients with peanut allergy","volume":"80","author":"Chinthrajah","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2026.01.044_bib65","doi-asserted-by":"crossref","first-page":"4759","DOI":"10.1172\/JCI138448","article-title":"Bruton's tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis","volume":"130","author":"Dispenza","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaip.2026.01.044_bib66","doi-asserted-by":"crossref","DOI":"10.1172\/JCI172335","article-title":"A phase II study of Bruton's tyrosine kinase inhibition for the prevention of anaphylaxis","volume":"133","author":"Suresh","year":"2023","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaip.2026.01.044_bib67","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.anai.2023.04.023","article-title":"Treatment of food allergy: oral immunotherapy, biologics, and beyond","volume":"131","author":"Sindher","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2026.01.044_bib68","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.anai.2023.01.029","article-title":"Jak out of the box: Targeting Bruton's tyrosine kinase, sialic acid-binding immunoglobulin-like lectin-8, and Janus kinase 1 in food allergy","volume":"131","author":"Berin","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2026.01.044_bib69","article-title":"JAK1 inhibition with abrocitinib decreases allergen-specific basophil and T-cell activation in pediatric peanut allergy","volume":"2","author":"Ramsey","year":"2023","journal-title":"J Allergy Clin Immunol Glob"},{"key":"10.1016\/j.jaip.2026.01.044_bib70","doi-asserted-by":"crossref","DOI":"10.1002\/hon.3308","article-title":"Bruton tyrosine kinase inhibitor monotherapy in B-cell lymphoma and risk of infection: a systematic review and meta-analysis of randomized controlled trials","volume":"42","author":"Zuber","year":"2024","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.jaip.2026.01.044_bib71","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/1744666X.2022.2014323","article-title":"The infection risks of JAK inhibition","volume":"18","author":"Adas","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.044_bib72","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3390\/vaccines12010082","article-title":"Vaccinations in selected immune-related diseases treated with biological drugs and JAK inhibitors-literature review and statement of experts from Polish Dermatological Society","volume":"12","author":"Narbutt","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jaip.2026.01.044_bib73","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1182\/bloodadvances.2021006574","article-title":"BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLL","volume":"6","author":"Pleyer","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaip.2026.01.044_bib74","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.630942","article-title":"Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects","volume":"9","author":"Estupinan","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.jaip.2026.01.044_bib75","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/1744666X.2022.2039122","article-title":"Recent issues in JAK inhibitor safety: perspective for the clinician","volume":"18","author":"Fleischmann","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.044_bib76","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","article-title":"The present and future of bispecific antibodies for cancer therapy","volume":"23","author":"Klein","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaip.2026.01.044_bib77","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.molimm.2023.02.005","article-title":"Polyspecificity - An emerging trend in the development of clinical antibodies","volume":"155","author":"Sandeep, Shinde","year":"2023","journal-title":"Mol Immunol"},{"key":"10.1016\/j.jaip.2026.01.044_bib78","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adf9561","article-title":"A therapeutic strategy to target distinct sources of IgE and durably reverse allergy","volume":"15","author":"Limnander","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaip.2026.01.044_bib79","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1365-2222.2011.03934.x","article-title":"The 2S albumin allergens of Arachis hypogaea, Ara h 2 and Ara h 6, are the major elicitors of anaphylaxis and can effectively desensitize peanut-allergic mice","volume":"42","author":"Kulis","year":"2012","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2026.01.044_bib80","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/j.1365-2222.2009.03273.x","article-title":"Effector activity of peanut allergens: a critical role for Ara h 2, Ara h 6, and their variants","volume":"39","author":"Porterfield","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2026.01.044_bib81","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/cea.12113","article-title":"Ara h 1 CD4+ T cell epitope-based peptides: candidates for a peanut allergy therapeutic","volume":"43","author":"Prickett","year":"2013","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2026.01.044_bib82","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/all.15966","article-title":"Phase 1 trial supports safety and mechanism of action of peptide immunotherapy for peanut allergy","volume":"79","author":"Voskamp","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2026.01.044_bib83","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jaci.2024.08.010","article-title":"Ara h 2-expressing cucumber mosaic virus-like particle (VLP Peanut) induces in vitro tolerogenic cellular responses in peanut-allergic individuals","volume":"155","author":"Layhadi","year":"2025","journal-title":"J Allergy Clin Immunol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219826001431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219826001431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T09:37:08Z","timestamp":1775554628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219826001431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":83,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2213219826001431"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2026.01.044","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologics and Novel Therapeutics in Food Allergy","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2026.01.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}